Literature DB >> 18199238

Schizoaffective disorder: diagnostic issues and future recommendations.

Gin S Malhi1, Melissa Green, Andrea Fagiolini, Eric D Peselow, Veena Kumari.   

Abstract

OBJECTIVE: Difficulties surrounding the classification of mixed psychotic and affective syndromes continue to plague psychiatric nosology. This paper addresses the controversy regarding the diagnostic validity of schizoaffective disorder (SAD), a diagnosis that is used in both DSM-IV and ICD-10 and one that encroaches on both schizophrenia (SCZ) and bipolar disorder (BD).
METHODS: A systematic synthesis of clinical and empirical literature, including evidence from cognitive, neurobiological, genetic, and epidemiological research, was undertaken with the aim of evaluating the utility of the SAD classification.
RESULTS: Distinctions between the diagnostic categories of SCZ, SAD and BD are not clearly demarcated by findings from neuropsychological, neuroimaging, molecular neurobiology, or genetic epidemiology studies. On the contrary, convergent evidence purports overlap across current diagnostic boundaries in the heritability and pathophysiology of psychotic and affective disorders. However, there are some disorder-specific findings.
CONCLUSIONS: Schizoaffective disorder is a prototypic boundary condition that epitomizes the pitfalls of the current categorical classification system. Future revisions to the DSM should consider the implementation of one of two alternative models to account for individuals presenting with mixed psychotic and affective symptoms. These include the views that (i) SAD is a comorbid set of symptoms that occur as a by-product of two separate disorders (SCZ and BD) or, that (ii) SAD exists as the mid-point on a continuum between SCZ and BD, such that the incorporation of these two disorders onto one dimension may be a suitable alternative. Hence the category SAD should be omitted in future revisions of DSM, allowing the development of meaningful nomenclature that rests upon further rigorous investigation of differences and similarities between disorders.

Entities:  

Mesh:

Year:  2008        PMID: 18199238     DOI: 10.1111/j.1399-5618.2007.00564.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  27 in total

Review 1.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

Review 2.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

3.  Viewing the elephant from 200 feet: reconstructing the schizophrenia syndrome.

Authors:  John A Sweeney
Journal:  Schizophr Res       Date:  2011-02-01       Impact factor: 4.939

Review 4.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

5.  Neuroanatomical heterogeneity of schizophrenia revealed by semi-supervised machine learning methods.

Authors:  Nicolas Honnorat; Aoyan Dong; Eva Meisenzahl-Lechner; Nikolaos Koutsouleris; Christos Davatzikos
Journal:  Schizophr Res       Date:  2017-12-21       Impact factor: 4.939

6.  A twin study of schizoaffective-mania, schizoaffective-depression, and other psychotic syndromes.

Authors:  Alastair G Cardno; Frühling V Rijsdijk; Robert M West; Irving I Gottesman; Nick Craddock; Robin M Murray; Peter McGuffin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-12-27       Impact factor: 3.568

Review 7.  Oral paliperidone: a review of its use in the management of schizoaffective disorder.

Authors:  Lily P H Yang
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

8.  Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different.

Authors:  A Owoso; C S Carter; J M Gold; A W MacDonald; J D Ragland; S M Silverstein; M E Strauss; D M Barch
Journal:  Psychol Med       Date:  2013-03-25       Impact factor: 7.723

9.  Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept.

Authors:  M L Hamshere; E K Green; I R Jones; L Jones; V Moskvina; G Kirov; D Grozeva; I Nikolov; D Vukcevic; S Caesar; K Gordon-Smith; C Fraser; E Russell; G Breen; D St Clair; D A Collier; A H Young; I N Ferrier; A Farmer; P McGuffin; P A Holmans; M J Owen; M C O'Donovan; N Craddock
Journal:  Br J Psychiatry       Date:  2009-07       Impact factor: 9.319

Review 10.  Is schizoaffective disorder a useful diagnosis?

Authors:  Stephan Heckers
Journal:  Curr Psychiatry Rep       Date:  2009-08       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.